FQ
SRPT icon

First Quadrant’s Sarepta Therapeutics SRPT Stock Holding History

First Quadrant’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-803
Closed -$88K – 806
2018
Q4 		$88K Hold
803
– – 0.01% 662
2018
Q3 		$130K Buy
+803
New +$110K ﹤0.01% 682

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

First Quadrant's SRPT Position: Q1 2019 in Review

First Quadrant sold out of Sarepta Therapeutics (SRPT) in Q1 2019, closing a stake of 803 shares — an estimated $88K sold.

First Quadrant first reported a position in SRPT in Q3 2018 and held it in 2 quarters. The position peaked at $130K in Q3 2018. 372 funds tracked by Wall St. Rank hold SRPT as of Q1 2019.

  • First Quadrant reported no remaining Sarepta Therapeutics position as of Q1 2019 after selling out during the quarter.
  • First Quadrant sold 803 Sarepta Therapeutics shares in Q1 2019, an estimated $88K.
  • First Quadrant first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 2 quarters.
  • First Quadrant's Sarepta Therapeutics position peaked at $130K in Q3 2018.
  • 372 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2019.

Based on First Quadrant's 13F filing for Q1 2019, filed 24 Apr 2019.